Citations (71)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Marcel A. Deken, Jules Gadiot, Ekaterina S. Jordanova, Ruben Lacroix, Melissa van Gool, Paula Kroon, Cristina Pineda, Marnix H. Geukes Foppen, Richard Scolyer, Ji-Ying Song, Inge Verbrugge, Christoph Hoeller, Reinhard Dummer, John B. A. G. Haanen, Georgina V. Long & Christian U. Blank. (2016) Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma. OncoImmunology 5:12.
Read now
Read now
Zhuo Ma, Lingjun Zhu, Xuan Luo, Sulan Zhai, Ping Li & Xuerong Wang. (2012) Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells. Cancer Biology & Therapy 13:11, pages 1009-1017.
Read now
Read now
Ayodele Ayoola, Amit Barochia, Kiran Belani & Chandra P. Belani. (2012) Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update. Cancer Investigation 30:5, pages 433-446.
Read now
Read now
Yikun Li, Songqing Fan, Junghui Koo, Ping Yue, Zhuo (Georgia) Chen, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri & Shi-Yong Sun. (2012) Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biology & Therapy 13:5, pages 272-280.
Read now
Read now
Cheng-Xiong Xu, Liqun Zhao, Ping Yue, Guofu Fang, Hui Tao, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri & Shi-Yong Sun. (2011) Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biology & Therapy 12:6, pages 549-555.
Read now
Read now
Xuerong Wang & Shi-Yong Sun. (2009) Enhancing mTOR-targeted cancer therapy. Expert Opinion on Therapeutic Targets 13:10, pages 1193-1203.
Read now
Read now
Articles from other publishers (65)
Xuejian Wang, Wenyan Jiang, Yanmei Du, Dongqi Zhu, Jian Zhang, Chunyan Fang, Fang Yan & Zhe-Sheng Chen. (2022) Targeting feedback activation of signaling transduction pathways to overcome drug resistance in cancer. Drug Resistance Updates 65, pages 100884.
Crossref
Crossref
Mahabub Alam, Hiroki Shima, Yoshitaka Matsuo, Nguyen Chi Long, Mitsuyo Matsumoto, Yusho Ishii, Nichika Sato, Takato Sugiyama, Risa Nobuta, Satoshi Hashimoto, Liang Liu, Mika K. Kaneko, Yukinari Kato, Toshifumi Inada & Kazuhiko Igarashi. (2022) mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine. Journal of Biological Chemistry 298:7, pages 102084.
Crossref
Crossref
Julie E. Bauman, Zhengjia Chen, Chao Zhang, James P. Ohr, Robert L. Ferris, Gerald M. McGorisk, Stephen Brandt, Sumathi Srivatsa, Amy Y. Chen, Conor E. Steuer, Dong M. Shin, Nabil F. Saba, Fadlo R. Khuri & Taofeek K. Owonikoko. (2022) A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer. Cancers 14:11, pages 2639.
Crossref
Crossref
Gloriana Ndembe, Ilenia Intini, Elisa Perin, Mirko Marabese, Elisa Caiola, Paolo Mendogni, Lorenzo Rosso, Massimo Broggini & Marika Colombo. (2022) LKB1: Can We Target an Hidden Target? Focus on NSCLC. Frontiers in Oncology 12.
Crossref
Crossref
Colin A. Bill, Christopher M. Allen & Charlotte M. Vines. (2022) C-C Chemokine Receptor 7 in Cancer. Cells 11:4, pages 656.
Crossref
Crossref
Shi-Yong Sun. (2020) mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?. Frontiers of Medicine 15:2, pages 221-231.
Crossref
Crossref
Jiajia Gu, Luxi Qian, Guojing Zhang, Nupam P. Mahajan, Taofeek K. Owonikoko, Suresh S. Ramalingam & Shi-Yong Sun. (2020) Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. Lung Cancer 150, pages 26-35.
Crossref
Crossref
Sara Zanini, Serena Renzi, Francesco Giovinazzo & Giovanna Bermano. (2020) mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Frontiers in Endocrinology 11.
Crossref
Crossref
Hesham M. Amin, Ajaykumar C. Morani, Najat C. Daw, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A. Menegaz, Deeksha Vishwamitra, Ghazaleh Eskandari, Bhawana George, Robert S. Benjamin, Shreyaskumar Patel, Juhee Song, Alexander J. Lazar, Wei-Lien Wang, Razelle Kurzrock, Alberto Pappo, Peter M. Anderson, Gary K. Schwartz, Dejka Araujo, Branko Cuglievan, Ravin Ratan, David McCall, Sana Mohiuddin, John A. Livingston, Eric R. Molina, Aung Naing & Joseph A. Ludwig. (2020) IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers 12:7, pages 1768.
Crossref
Crossref
Hongjing Zang, Guoqing Qian, Dan Zong, Songqing Fan, Taofeek K. Owonikoko, Suresh S. Ramalingam & Shi‐Yong Sun. (2020) Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer 126:9, pages 2024-2033.
Crossref
Crossref
Asiya Batool, Sheikh Tahir Majeed, Sabreena Aashaq, Rabiya Majeed, Nadiem Nazir Bhat & Khurshid Iqbal Andrabi. (2019) Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1. Molecular and Cellular Biochemistry 465:1-2, pages 13-26.
Crossref
Crossref
Dania Movia, Despina Bazou & Adriele Prina-Mello. (2019) ALI multilayered co-cultures mimic biochemical mechanisms of the cancer cell-fibroblast cross-talk involved in NSCLC MultiDrug Resistance. BMC Cancer 19:1.
Crossref
Crossref
Tianying Yang, Jiawei Li, Ruimin Li, Chunchen Yang, Weitao Zhang, Yue Qiu, Cheng Yang & Ruiming Rong. (2019) Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell Interaction. Current Gene Therapy 19:2, pages 81-92.
Crossref
Crossref
Hossein Javid, Arash Soltani, Fariba Mohammadi & Seyed Isaac Hashemy. (2019) Emerging roles of microRNAs in regulating the mTOR signaling pathway during tumorigenesis. Journal of Cellular Biochemistry 120:7, pages 10874-10883.
Crossref
Crossref
Adam X. Sang, Marla C. McPherson, Geoffrey T. Ivison, Xiumei Qu, Joseph Rigdon, Carlos O. Esquivel, Sheri M. Krams & Olivia M. Martinez. (2019) Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival. American Journal of Transplantation 19:5, pages 1305-1314.
Crossref
Crossref
Xian-bo Huang, Chun-mei Yang, Qing-mei Han, Xiu-jin Ye, Wen Lei & Wen-bin Qian. (2018) MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells. Acta Pharmacologica Sinica 39:12, pages 1894-1901.
Crossref
Crossref
Guoqing Qian, Weilong Yao, Shuo Zhang, Richa Bajpai, William D. Hall, Mala Shanmugam, Sagar Lonial & Shi-Yong Sun. (2018) Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Cancer Letters 435, pages 44-54.
Crossref
Crossref
Qinghua Luo, Li Zhang, Feng Wei, Qiang Fang, Fei Bao, Shijiang Mi, Nan Li, Chengming Wang, Yan Liu & Changchun Tu. (2018) mTORC1 Negatively Regulates the Replication of Classical Swine Fever Virus Through Autophagy and IRES-Dependent Translation. iScience 3, pages 87-101.
Crossref
Crossref
Puyu Shi, You-Take Oh, Liang Deng, Guojing Zhang, Guoqing Qian, Shuo Zhang, Hui Ren, Grant Wu, Benjamin LegendreJrJr, Emily Anderson, Suresh S. Ramalingam, Taofeek K. Owonikoko, Mingwei Chen & Shi-Yong Sun. (2017) Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation. Clinical Cancer Research 23:21, pages 6567-6579.
Crossref
Crossref
Rui Li, Chunyong Ding, Jun Zhang, Maohua Xie, Dongkyoo Park, Ye Ding, Guo Chen, Guojing Zhang, Melissa Gilbert-Ross, Wei Zhou, Adam I. Marcus, Shi-Yong Sun, Zhuo G. Chen, Gabriel L. Sica, Suresh S. Ramalingam, Andrew T. Magis, Haian Fu, Fadlo R. Khuri, Walter J. Curran, Taofeek K. Owonikoko, Dong M. Shin, Jia Zhou & Xingming Deng. (2017) Modulation of Bax and mTOR for Cancer Therapeutics. Cancer Research 77:11, pages 3001-3012.
Crossref
Crossref
Beibei Mao, Shanyun Gao, Yiran Weng, Liangren Zhang & Lihe Zhang. (2017) Design, synthesis, and biological evaluation of imidazo[1,2- b ]pyridazine derivatives as mTOR inhibitors. European Journal of Medicinal Chemistry 129, pages 135-150.
Crossref
Crossref
Salah-Eddine Lamhamedi-Cherradi, Brian A. Menegaz, Vandhana Ramamoorthy, Deeksha Vishwamitra, Ying Wang, Rebecca L. Maywald, Adriana S. Buford, Izabela Fokt, Stanislaw Skora, Jing Wang, Aung Naing, Alexander J. Lazar, Eric M. Rohren, Najat C. Daw, Vivek Subbiah, Robert S. Benjamin, Ravin Ratan, Waldemar Priebe, Antonios G. Mikos, Hesham M. Amin & Joseph A. Ludwig. (2016) IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. Journal of the National Cancer Institute 108:12, pages djw182.
Crossref
Crossref
Pei Shi Ong, Louis Z. Wang, Xiaoyun Dai, Sheng Hsuan Tseng, Shang Jun Loo & Gautam Sethi. (2016) Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Frontiers in Pharmacology 7.
Crossref
Crossref
Puyu Shi, You-Take Oh, Guojing Zhang, Weilong Yao, Ping Yue, Yikun Li, Rajani Kanteti, Jacob Riehm, Ravi Salgia, Taofeek K. Owonikoko, Suresh S. Ramalingam, Mingwei Chen & Shi-Yong Sun. (2016) Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Letters 380:2, pages 494-504.
Crossref
Crossref
K. B. Arun, U. Aswathi, V. V. Venugopal, T. S. Madhavankutty & P. Nisha. (2016) Nutraceutical properties of cumin residue generated from Ayurvedic industries using cell line models. Journal of Food Science and Technology 53:10, pages 3814-3824.
Crossref
Crossref
Mark A. Weinberg. (2016) RES-529. Anti-Cancer Drugs 27:6, pages 475-487.
Crossref
Crossref
Xiaobo Chen, Changgui Dong, Priscilla T.Y. Law, Matthew T.V. Chan, Zhaoliang Su, Shengjun Wang, William K.K. Wu & Huaxi Xu. (2015) MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Gynecologic Oncology 139:3, pages 513-519.
Crossref
Crossref
T. Nakamura, T. Nakao, N. Yoshimura & E. Ashihara. (2015) Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells. American Journal of Transplantation 15:9, pages 2364-2377.
Crossref
Crossref
YONG-ZHI SAN, YU LIU, YU ZHANG, PING-PING SHI & YU-LAN ZHU. (2015) Peroxisome proliferator-activated receptor-γ agonist inhibits the mammalian target of rapamycin signaling pathway and has a protective effect in a rat model of status epilepticus. Molecular Medicine Reports 12:2, pages 1877-1883.
Crossref
Crossref
Weilong Yao, Ping Yue, Guojing Zhang, Taofeek K. Owonikoko, Fadlo R. Khuri & Shi-Yong Sun. (2015) Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Letters 364:1, pages 70-78.
Crossref
Crossref
Mark Livingstone, Kristina Sikström, Philippe A. Robert, Gilles Uzé, Ola Larsson & Sandra Pellegrini. (2015) Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes. PLOS ONE 10:7, pages e0133482.
Crossref
Crossref
Junghui Koo, Xuerong Wang, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri & Shi-Yong Sun. (2015) GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget 6:11, pages 8974-8987.
Crossref
Crossref
Feng Wei, Yandong Zhang, Li Geng, Ping Zhang, Guangyi Wang & Yan Liu. (2015) mTOR Inhibition Induces EGFR Feedback Activation in Association with Its Resistance to Human Pancreatic Cancer. International Journal of Molecular Sciences 16:2, pages 3267-3282.
Crossref
Crossref
BJÖRN GEORGI, NINA KORZENIEWSKI, BORIS HADASCHIK, CARSTEN GRÜLLICH, WILFRIED ROTH, HOLGER SÜLTMANN, SASCHA PAHERNIK, MARKUS HOHENFELLNER & STEFAN DUENSING. (2014) Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review). International Journal of Oncology 45:4, pages 1337-1344.
Crossref
Crossref
Meiguo Xin, Rui Li, Maohua Xie, Dongkyoo Park, Taofeek K. Owonikoko, Gabriel L. Sica, Patrick E. Corsino, Jia Zhou, Chunyong Ding, Mark A. White, Andrew T. Magis, Suresh S. Ramalingam, Walter J. Curran, Fadlo R. Khuri & Xingming Deng. (2014) Small-molecule Bax agonists for cancer therapy. Nature Communications 5:1.
Crossref
Crossref
Sean T. Bailey, Bing Zhou, Jeffrey S. Damrauer, Bhavani Krishnan, Harper L. Wilson, Aleisha M. Smith, Mingqing Li, Jen Jen Yeh & William Y. Kim. (2014) mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. PLoS ONE 9:9, pages e104413.
Crossref
Crossref
Pankit VachhaniPrithviraj Bose, Mohamed Rahmani & Steven Grant. (2014) Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiological Genomics 46:13, pages 448-456.
Crossref
Crossref
P. Y. Wen, S. M. Chang, K. R. Lamborn, J. G. Kuhn, A. D. Norden, T. F. Cloughesy, H. I. Robins, F. S. Lieberman, M. R. Gilbert, M. P. Mehta, J. Drappatz, M. D. Groves, S. Santagata, A. H. Ligon, W. K. A. Yung, J. J. Wright, J. Dancey, K. D. Aldape, M. D. Prados & K. L. Ligon. (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-Oncology 16:4, pages 567-578.
Crossref
Crossref
Shuo You, Rui Li, Dongkyoo Park, Maohua Xie, Gabriel L. Sica, Ya Cao, Zhi-Qiang Xiao & Xingming Deng. (2014) Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer. Molecular Cancer Therapeutics 13:3, pages 606-616.
Crossref
Crossref
Rosário Pinto-Leite, Regina Arantes-Rodrigues, Rita Ferreira, Carlos Palmeira, Aura Colaço, Vítor Moreira da Silva, Paula Oliveira & Lúcio Lara Santos. (2014) Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations 32:1, pages 41.e11-41.e22.
Crossref
Crossref
Yoshinori Tsukumo, Mathieu Laplante, Armen Parsyan, Davide Ruggero & Bruno Fonseca. 2014. Translation and Its Regulation in Cancer Biology and Medicine. Translation and Its Regulation in Cancer Biology and Medicine
307
343
.
Christine A. Ciunci, Rodolfo F. Perini, Anjali N. Avadhani, Hyunseon C. Kang, Weijing Sun, Maryann Redlinger, Kathleen Harlacker, Keith T. Flaherty, Bruce J. Giantonio, Mark A. Rosen, Chaitanya R. Divgi, Hee Kwon Song, Sarah Englander, Andrea Troxel, Mitchell Schnall & Peter J. O'Dwyer. (2014) Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 120:1, pages 77-85.
Crossref
Crossref
Feng Wei, Yan Liu, Yanhai Guo, An Xiang, Guangyi Wang, Xiaochang Xue & Zifan Lu. (2013) miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Molecular Cancer 12:1.
Crossref
Crossref
Rui Li, Zhongliang Hu, Shi-Yong Sun, Zhuo G. Chen, Taofeek K. Owonikoko, Gabriel L. Sica, Suresh S. Ramalingam, Walter J. Curran, Fadlo R. Khuri & Xingming Deng. (2013) Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 12:10, pages 2200-2212.
Crossref
Crossref
Shi-Yong Sun. (2013) mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Letters 340:1, pages 1-8.
Crossref
Crossref
Rui Li, Shuo You, Zhongliang Hu, Zhuo G. Chen, Gabriel L. Sica, Fadlo R. Khuri, Walter J. Curran, Dong M. Shin & Xingming Deng. (2013) Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer. PLoS ONE 8:9, pages e74670.
Crossref
Crossref
Yikun Li, Xuerong Wang, Ping Yue, Hui Tao, Suresh S. Ramalingam, Taofeek K. Owonikoko, Xingming Deng, Ya Wang, Haian Fu, Fadlo R. Khuri & Shi-Yong Sun. (2013) Protein Phosphatase 2A and DNA-dependent Protein Kinase Are Involved in Mediating Rapamycin-induced Akt Phosphorylation. Journal of Biological Chemistry 288:19, pages 13215-13224.
Crossref
Crossref
Tetsuo Nishi, Kenta Iwasaki, Norifumi Ohashi, Chie Tanaka, Daisuke Kobayashi, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Takaaki Kobayashi & Yasuhiro Kodera. (2013) Phosphorylation of 4E-BP1 predicts sensitivity to everolimus in gastric cancer cells. Cancer Letters 331:2, pages 220-229.
Crossref
Crossref
Benjamin Blaser, Laurent Waselle, Anne Dormond-Meuwly, Marc Dufour, Didier Roulin, Nicolas Demartines & Olivier Dormond. (2012) Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC Cancer 12:1.
Crossref
Crossref
Hui Ren, Mingwei Chen, Ping Yue, Hui Tao, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri & Shi-Yong Sun. (2012) The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo. Cancer Letters 325:2, pages 139-146.
Crossref
Crossref
Toran Sanli, Yaryna Storozhuk, Katja Linher-Melville, Robert G. Bristow, Keith Laderout, Benoit Viollet, James Wright, Gurmit Singh & Theodoros Tsakiridis. (2012) Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells. Radiotherapy and Oncology 102:3, pages 459-465.
Crossref
Crossref
Shinya Iida, Yasuhiro Miki, Katsuhiko Ono, Jun-ichi Akahira, Yasuhiro Nakamura, Takashi Suzuki & Hironobu Sasano. (2012) Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor. Molecular and Cellular Endocrinology 350:1, pages 99-106.
Crossref
Crossref
Lokesh Nagaprashantha, Neha Vartak, Sangeeta Awasthi, Sanjay Awasthi & Sharad S. Singhal. (2011) Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors. Pharmaceutical Research 29:3, pages 621-636.
Crossref
Crossref
Yan Liu, Shi-Yong Sun, Taofeek K. Owonikoko, Gabriel L. Sica, Walter J. Curran, Fadlo R. Khuri & Xingming Deng. (2012) Rapamycin Induces Bad Phosphorylation in Association with Its Resistance to Human Lung Cancer Cells. Molecular Cancer Therapeutics 11:1, pages 45-56.
Crossref
Crossref
J. Chen. (2011) Multiple signal pathways in obesity-associated cancer. Obesity Reviews 12:12, pages 1063-1070.
Crossref
Crossref
Tongrui Liu, Rami Yacoub, LaTonia D. Taliaferro-Smith, Shi-Yong Sun, Tisheeka R. Graham, Ryan Dolan, Christine Lobo, Mourad Tighiouart, Lily Yang, Amy Adams & Ruth M. O'Regan. (2011) Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells. Molecular Cancer Therapeutics 10:8, pages 1460-1469.
Crossref
Crossref
Cheng-Xiong Xu, Yikun Li, Ping Yue, Taofeek K. Owonikoko, Suresh S. Ramalingam, Fadlo R. Khuri & Shi-Yong Sun. (2011) The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS ONE 6:6, pages e20899.
Crossref
Crossref
Pedro J. Beltran, Young-Ah Chung, Gordon Moody, Petia Mitchell, Elaina Cajulis, Steven Vonderfecht, Richard Kendall, Robert Radinsky & Frank J. Calzone. (2011) Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models. Journal of Pharmacology and Experimental Therapeutics 337:3, pages 644-654.
Crossref
Crossref
Marc Dufour, Anne Dormond-Meuwly, Nicolas Demartines & Olivier Dormond. (2011) Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives. Cancers 3:2, pages 2478-2500.
Crossref
Crossref
Lei Fu, Yi-Dan Lin, Heath A Elrod, Ping Yue, Youtake Oh, Bo Li, Hui Tao, Georgia Z Chen, Dong M Shin, Fadlo R Khuri & Shi-Yong Sun. (2010) c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL. Molecular Cancer 9:1.
Crossref
Crossref
Katharine A. Price, Christopher G. Azzoli, Lee M. Krug, Maria C. Pietanza, Naiyer A. Rizvi, William Pao, Mark G. Kris, Gregory J. Riely, Robert T. Heelan, Maria E. Arcila & Vincent A. Miller. (2010) Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:10, pages 1623-1629.
Crossref
Crossref
Christina Barbara Ching & Donna Elizabeth Hansel. (2010) Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway. Laboratory Investigation 90:10, pages 1406-1414.
Crossref
Crossref
Paul Dent, David T. Curiel, Paul B. Fisher & Steven Grant. (2009) Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resistance Updates 12:3, pages 65-73.
Crossref
Crossref
Heidi A Lane & Madlaina Breuleux. (2009) Optimal targeting of the mTORC1 kinase in human cancer. Current Opinion in Cell Biology 21:2, pages 219-229.
Crossref
Crossref
Madlaina Breuleux & Heidi A. Lane. 2010. mTOR Pathway and mTOR Inhibitors in Cancer Therapy. mTOR Pathway and mTOR Inhibitors in Cancer Therapy
149
178
.